Hims & Hers Shares Crater 15% After Wider Net Losses, GLP Shift…
Hims & Hers Health (NYSE: HIMS) reported a larger first-quarter loss and outlined a lower earnings outlook, pressuring shares in premarket trading Tuesday.
The results came as the digital health company changed its weight-loss drug strategy. Hims & Hers reached an agreement with Novo Nordisk (NYSE: NVO) in March to offer Wegovy, Novo’s branded GLP-1 weight-loss treatment, through its platform. As part of that agreement, Hims & Hers committed to stop broad advertising and marketing of compounded GLP-1 products once it begins receiving Novo Nordisk’s branded drugs. The arrangement moves the company away from a business line that had drawn investor attention and regulatory scrutiny.
Hims & Hers reported a first-quarter net loss of $92 million, compared with a loss of about $50 million a year earlier. Adjusted EBITDA declined to $44 million from $91 million.Revenue increased 4% to $608 million. Average monthly revenue per subscriber fell to $80 from $85 in the prior-year quarter.
For the second quarter, the company projected revenue of $680 million to $700 million and adjusted EBITDA of up to $55 million. For the full year, Hims & Hers forecast revenue of up to $3 billion and adjusted EBITDA of up to $350 million.
Shares were recently down 15.5% in premarket trading. Citi analysts called the forecast “mixed” and said the second-quarter outlook was below the firm’s estimates.
The company’s GLP-1 business has been a source of volatility for the stock. Hims & Hers previously sold lower-cost compounded versions of weight-loss drugs through a regulatory allowance tied to drug shortages. Novo Nordisk said in February that it would sue the company over copycat Wegovy products and said the practice raised patient safety concerns. Hims & Hers later pulled the pill.
Citi analysts said the quarter marked a transition as Hims & Hers reduces its reliance on compounded GLP-1s.
Novo Nordisk CEO Mike Doustdar told CNBC in March that the new arrangement differed from the companies’ prior dealings because Hims & Hers had agreed not to advertise, promote or mass-market compounded products after receiving Novo’s branded treatments.
About Hims & Hers Health
Hims & Hers Health (NYSE: HIMS) is a digital health company founded in 2017 and headquartered in San Francisco. The company provides telehealth consultations and access to treatments across areas including sexual health, hair loss, dermatology, mental health and weight management.
At the time of publishing, Stocks.News does not hold positions in companies mentioned in the article.